However, Nesbitt et al. achieved a similar effect for corresponding target and off-target tumours with an SDT platform using sensitizer-carrying microbubbles and multiple treatments within an 11-day period, in the presence of an immune checkpoint PD-L1 inhibitor (Nesbitt et al. 2021). Here, CD274 is linked to neoplasm.